CD74
HLA class II histocompatibility antigen gamma chain
As of the edition of 20 October 2026, CD74 (HLA class II histocompatibility antigen gamma chain, UniProt P04233) has 3 drugs tested at it and 4 companies on the list, 4 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P04233
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 24
- Disease areas
- Blood and lymph; Cancer; Immune system; Heart and blood vessels; Infections; Lungs and airways; Nervous system; Pregnancy and women's health
- Registered trials of its drugs
- 11
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 3 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Milatuzumab | Stopped | Phase 2 | none listed |
| Bezetabart debotansine | Stopped | Phase 2 | none listed |
| S227928 | Stopped | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Servier | Route A |
| Gilead Sciences | Route A |
| BioNova Pharmaceuticals | Route A |
The other 1 company at CD74
In the product4 companies in all; 1 is not named here, and no score is.
See the 4 companies at CD74, ranked, with the facts behind eachRequest access. Nothing is shown until you do.